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OBJECTIVE—To determine whether the medial amygdalar
nucleus (MAN) represents a novel brain glucose-sensing region
involved in the detection of hypoglycemia and generation of a
counterregulatory hormone response.
RESEARCH DESIGN AND METHODS—Fura-2 calcium imag-
ing was used to assess glucose responsivity in neurons isolated
from the MAN and single-cell real-time reverse transcription PCR
used to examine gene expression within glucose-responsive
neurons. In vivo studies with local MAN perfusion of the gluco-
privic agent, 2-deoxyglucose (2-DG), under normal and hypogly-
cemic conditions and also after MAN lesioning with ibotenic
acid, were used to examine the functional role of MAN glucose
sensors. In addition, retrograde neuronal tracer studies were
used to examine reciprocal pathways between the MAN and the
ventromedial hypothalamus (VMH).
RESULTS—The MAN contains a population of glucose-sensing
neurons (13.5%), which express glucokinase, and the selective
urocortin 3 (UCN3) receptor CRH-R2, but not UCN3 itself.
Lesioning the MAN suppressed, whereas 2-DG infusion ampliﬁed,
the counterregulatory response to hyperinsulinemic hypoglyce-
mia in vivo. However, 2-DG infusion to the MAN or VMH under
normoglycemic conditions had no systemic effect. The VMH is
innervated by UCN3 neurons that arise mainly from the MAN,
and 1/3 of MAN UCN3 neurons are active during mild
hypoglycemia.
CONCLUSIONS—The MAN represents a novel limbic glu-
cose-sensing region that contains characteristic glucokinase-
expressing glucose-sensing neurons that respond directly to
manipulations of glucose availability both in vitro and in vivo.
Moreover, UCN3 neurons may provide feedback inhibitory reg-
ulation of the counterregulatory response through actions within
the VMH and the MAN. Diabetes 59:2646–2652, 2010
I
n some patients with type 1 (and 2) diabetes, the
ability to detect and respond to hypoglycemia is
markedly impaired (1). Specialized glucose-sensing
neurons exist within discrete regions of the brain
and are thought to have a particular role in the regulation
of glucose homeostasis. Glucose-excited neurons increase
their activity as glucose levels rise, and glucose-inhibited
neurons increase their activity as glucose levels fall (2,3).
The mechanisms used by glucose-excited neurons to de-
tect a fall in the glucose level to which they are exposed
are thought to resemble those used by the classical
glucose sensor, the pancreatic -cell, with in particular
roles for glucokinase and the ATP-sensitive potassium
channel (KATP) (1), while glucose-inhibited neurons also
use glucokinase, as well as nitric oxide and adenosine
5-monophosphate-activated protein kinase to modulate
their glucose sensing (4–6). Glucose-sensing neurons
are located in a number of brain regions, although only
those present in the ventromedial (VMH) (7–9), dorso-
medial, and paraventricular hypothalamus (10,11) to
date have been shown in vivo, in rodent models, to
modulate counterregulatory responses during insulin-
induced hypoglycemia.
We have recently shown that urocortin 3 (UCN3), a
member of the corticotrophin-releasing hormone (CRH)
family of neuropeptides, and a selective ligand for the
CRH-R2 receptor, may regulate the magnitude of the
counterregulatory response to hypoglycemia through ac-
tions in the VMH (12,13). UCN3 nerve terminals provide a
dense innervation to the shell of the VMH and tubercle
area (14). The cell bodies of UCN3 neurons are found
predominantly in the medial amygdalar nucleus (MAN),
the hypothalamic medial preoptic nucleus, and the rostral
perifornical area lateral to the paraventricular hypotha-
lamic nucleus (14). Intriguingly, the pancreatic isoform of
glucokinase, the rate-limiting step of glucose oxidation
and a key step in the glucose-sensing mechanism (2,6), is
also expressed in the MAN (15). This study examined the
hypothesis that the MAN may represent a novel central
glucose-sensing region and, moreover, that it might be
directly linked with the VMH via UCN3 neurons.
RESEARCH DESIGN AND METHODS
Male Sprague-Dawley rats (mean  SEM wt, 305  4 g) were housed in the
local Animal Resource Center with water and chow pellet available ad libitum.
The animal care and experimental protocols were reviewed and approved by
Yale University Institutional Animal Care and Use Committee and the Institu-
tional Animal Care and Use Committee of the East Orange Veterans Affairs
Medical Center.
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described in detail elsewhere (8,16). In brief, one week prior to each study, all
animals were anesthetized with an intraperitoneal injection (1 ml/kg) of a
mixture of xyzaline (20 mg/ml; AnaSed, Lloyd Laboratories Inc.) and ketamine
(100 mg/ml; Ketaset, Wyeth) at a ratio of 1:2 (vol/vol). Vascular catheters
[PE50 tubing with a tip made from silastic laboratory tubing (0.51 mm inner
diameter)] were inserted via a neck incision into the internal jugular vein and
carotid artery. After catheter implantation, cannula guides were stereotaxi-
cally inserted, bilaterally to the MAN (coordinates from bregma, anterior-
posterior [AP]  2.80 mm, medio-lateral [ML]  3.3 mm, and dorso-
ventral [DV]  8.9 mm at an angle of 90°) or VMH (coordinates AP  2.6 mm;
ML  0.5 mm; DV  9.4 mm). Guide cannula were designed to reach a point
1 mm proximal to the target nucleus, limiting gliosis in the region where
microinjection would take place 7 days after guide catheter insertion.
Lesion study. At the initial surgery, as described above, and instead of guide
cannula insertion, each rat received bilateral microinjections to the MAN of 2
pg of ibotenic acid (n  6) using a 1 l Hamilton syringe (total volume 200 nl
over 30 min), after which the skin was closed with wound clips. Sham-lesion
rats received the identical surgical procedure but were administered saline
rather than ibotenic acid (n  9).
Normoglycemic study. Seven days after surgery, overnight fasted rats had
their catheters opened and were allowed to acclimatize over 90 min. Bilateral
26-guage injection needles, designed to extend 1 mm beyond the tip of the
guide cannula, were then inserted into each MAN or VMH, and each rat
received bilateral microinfusions (1 l given at a rate of 0.033 l/min for 30
min) of 10 mmol/l 2-deoxyglucose (2-DG), a nonmetabolizable form of glucose
that creates local glucopenia, or artiﬁcial extracellular ﬂuid (aECF), depend-
ing on the study. Venous samples for measurement of plasma glucose were
taken every 10 min and for glucagon and epinephrine preinjection (t  0 min)
and at 30 and 60 min after microinjection.
Hyperinsulinemic hypoglycemic study. A modiﬁed hyperinsulinemic glu-
cose clamp was used to produce a standardized hypoglycemic stimulus, as
described previously (17). Thirty min after bilateral MAN microinfusions of
2-DG (n  6) or artiﬁcial aECF (n  9), a constant 20 mU/kg/min infusion of
insulin (Human Regular Insulin, Lilly, IL) was started. Both solutions were
mixed with 4% wheat germ agglutinin (WGA) to conﬁrm the location of
microinjection (supplementary Fig. 1, available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-0995/DC1). The plasma
glucose was allowed to fall to 70 mg/dl (3.9 mmol/l), where it was maintained
for 90 min using 20% dextrose, with the dextrose infusion rate adjusted every 5
min based on plasma glucose determinations. Blood samples for measurement of
epinephrine, glucagon, and insulin were taken at 0, 60, and 90 min. Plasma
glucose was measured by glucose oxidase method (Glucose Direct; Analox
Instruments, Lunenberg, MA). Catecholamine analysis was performed by high-
performance liquid chromatography using electrochemical detections (ESA,
Acton, MA); plasma insulin and glucagon were measured by radioimmunoassay
(Millipore, Temecula, CA).
Retrograde neuronal tracer studies. The retrograde tracing technique has
been described previously (18). Brieﬂy, each rat was microinjected bilaterally
to the VMH or MAN (coordinates as above) with the retrograde neuronal
tracer WGA or 4% ﬂuorogold dissolved in aECF and delivered through a glass
micropipette with tip diameter 10–15 m by passing 2-A positive current
pulse (7 s on/off) for 10 min. The rats were then allowed to recover for 7
days before undergoing a 90-min hyperinsulinemic (20 mU/kg/min) hypogly-
cemic (70 mg/dl) or hyperinsulinemic euglycemic (120 mg/dl) clamp, as
described above.
Immunohistochemistry. The immunohistochemistry protocol used has been
described in detail previously (18,19). Brieﬂy, analysis was performed on
every six 40-m-thick frontal sections. Sections were washed in PBS for 10
min and then pretreated in 0.3% H2O2 f o r1ht oblock endogenous peroxidase.
They were then incubated overnight at room temperature with 1:1,000 rabbit
anti-UCN antibody (1:2000; a gift from Dr. W. Vale) in 0.3% fresh normal
donkey serum, goat anti-WGA (1:1,000; Vector) and PBT-azide (0.02% sodium
azide and 0.04% Triton X-100 in PBS). The next day, sections were incubated
with biotinylated donkey anti-rabbit antibody (Jackson Laboratories; 1:500)
for 1 h, followed by incubation with a cocktail of Alexa Fluor 594-conjugated
Streptavidin (Molecular Probes, Eugene, OR; 1:1K) and Alexa Fluor 488-
conjugated chicken anti-goat antibody (1:400) for 1 h. After mounting on
polylysine slides, the sections were cover-slipped with antifade mount me-
dium for ﬂuorescence (Vectashield, Vector, CA). Dual ﬂuorescence images in
the MAN from the representative brain were taken with a digital camera.
Counting of dual staining for UCN3 and WGA was performed in three brains.
All single-labeled UCN3 neurons and dual-labeled neurons for UCN3 and WGA
in the MAN were counted. Cytoarchitectonic areas in the amygdala were
determined with reference to the atlas of Paxinos and Watson (20). Light-
microscope images in the MAN and its adjacent regions from a representative
brain were taken with a digital camera. The digital images were arranged in
the software Canvas (Deneba System, Miami, FL). The border of the MAN, its
adjacent structures, and distribution of single labeling of UCN3 neurons were
drawn using Canvas software. For triple staining, immunoﬂuorescence serial
sections from the brains of ﬂuorogold-injected rats were incubated overnight
with a mixture of 1 g/ml anti-Fos goat antibody (1:1K; Santa Cruz) and
anti-UCN3 rabbit serum (1:2,000). After a rinse with PBS-X, the sections were
incubated for 1 h with 10 g/ml biotinylated anti-rabbit IgG donkey antibody
(Jackson) and then for 1 h with a mixture of 1 g/ml Alexa488-conjugated
chicken anti-goat antibody (1:400; Molecular Probes) and 1 g/ml Alexa594
Streptavidin-conjugated antibody (Molecular Probes). Sections were observed
under an epiﬂuorescence microscope Olympus BX-50 with appropriate ﬁlter
sets for Alexa488 (excitation, 450–490 nm; emission, 514–565 nm); Alexa594
(excitation, 530–585 nm; emission, 615 nm) and ﬂuorogold (excitation,
359–371 nm; emission, 397–590 nm). Although Alexa488 ﬂuorescence could be
partially seen with the ﬁlter set for ﬂuorogold, Fos-immunoreactive neuropil
with Alexa488 ﬂuorescence was easily differentiated from retrograde labeled
cell bodies with ﬂuorogold ﬂuorescence. The counting of triple staining for
UCN3, Fos, and ﬂuorogold was performed in three brains. All single-labeled
UCN3 neurons and dual-labeled and triple-labeled neurons in the MAN were
counted.
MAN mRNA assays by quantitative real-time PCR. Frozen brains were cut
on a cryostat at 12°C and placed in RNAlater (Ambion, Foster City, CA) until
being micropunched. Micropunches of the MAN were performed by modiﬁ-
cations of the method of Palkovits (21), where brain micropunches are made
under microscope guidance from brain slices placed on the base of a
stereotaxic frame. Micropunched brain areas were sonicated in a guanidinium
thiocyanate solution and puriﬁed using magnetic beads (Ambion MagMax-96).
Quantitation of mRNA was carried out by real-time quantitative PCR (QPCR)
as previously described (22). Primer sets for each mRNA were designed by
reference to published sequences, and their speciﬁcity was veriﬁed using
Genebank. Primers and their sequence-speciﬁc FAM-labeled probes prepared
by Applied Biosystems were sequenced and then quantiﬁed with an Applied
Biosystems 7,700 real-time PCR system set for 40 PCR cycles. Standard curves
were generated from serially diluted pooled samples for each probe and for
constitutively expressed mRNA (cyclophilin) to control for differences in
ampliﬁcation efﬁciency and micropunch size. Results were calculated from
the standard curves relative to cyclophilin mRNA levels in the same samples.
Fura-2 calcium imaging to assess glucose-induced changes in intracel-
lular calcium ([Ca
2]i) oscillations. Studies were carried out in 3–4 week
old male Sprague-Dawley rats (Charles River). The MAN punched cells were
dissociated with papain (2 mg/ml, 30 min, 37°C) and mechanically triturated.
Cells were plated onto cover slips and allowed to adhere for 60 min before
loading with the Ca
2	 ﬂuorophore fura-2 acetoxy methyl ester (Molecular
Probes) for 20 min in Hank’s balanced salt solution buffer containing 2.5
mmol/l glucose, washed twice, and transferred to a microscope chamber held
at 37°C. Fura-2 ﬂuorescent images were acquired every5sb yalternating
excitation at 340 and 380 nm using a cooled, charge-coupled device camera at
420–600 nm emission. Changes in glucose were maintained for 10 min after
addition. Cells were classiﬁed as glucose-responsive in 
500 neurons by
signiﬁcant ([Ca
2	]i) ﬂuctuations (as area under the curve) after changes in
glucose concentrations using Origin 7.0 software (OriginLab). Neurons were
classiﬁed as glucose-excited, glucose-inhibited, and nonglucosensing, as pre-
viously described (7). Cytoplasms of individual characterized neurons were
then collected for single-cell QPCR (sc-QPCR) as previously described (23);
analysis was according to previous standards.
sc-QPCR. After characterization by Ca
2	 imaging, cytoplasmic mRNA of
individually imaged cells was analyzed by sc-QPCR. Cytoplasm from each
neuron was aspirated into a micropipette that was preﬁlled with DEPC-treated
water containing 1 lR N ASE OUT RNase inhibitor (Invitrogen, Carlsbad, CA).
Subsequently, synthesis was performed with Superscript II ﬁrst-strand syn-
thesis kit (Invitrogen) following the manufacturer’s directions. The RT reac-
tion was incubated at 42°C for 50 min after heat inactivation at 70°C. cDNA
was puriﬁed to completely remove inhibitory RT components by slight
modiﬁcation of the methods described by Liss (24). After the puriﬁcation of
single-cell cDNA, QPCR was performed using speciﬁc primers. Glial ﬁbrillary
acidic protein was used to exclude astrocytes, and -actin was used as an
internal control for constitutively expressed mRNA. Primer sequences were
designed using Biology WorkBench Primer design software. Ampliﬁcation
was carried out in a LightCycler (Roche Perkin-Elmer, Foster City, CA), using
40 cycles (95°C, 1 s; 56–63°C, 2 s; and 68°C, 30 s) with Advantage 2
Polymerase Mix (BD Biosciences, Palo Alto, CA). Ampliﬁed products were
run directly on a 1.5% agarose gel and visualized by ethidium bromide staining.
Gels were imaged and photo inverted for presentation. To optimize conditions
for primer ampliﬁcation and standardize for the linearity of the ampliﬁcation
process, hypothalamic cDNA was used.
For glucagon and epinephrine, differences between treatments were
assessed via repeated-measures ANOVA and based on hormonal readings
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Mean data were compared using a two-tailed Student t test. For all
analyses, signiﬁcance was assigned at the P  0.05 level. Data are
presented as mean  SEM.
RESULTS
The MAN contains glucose-sensing neurons. Of 522
individual MAN neurons examined using fura-2 calcium
imaging, 13.5% were glucose-sensing (Table 1). Six percent
were glucose-excited, and 7.5% were glucose-inhibited
(Fig. 1). By sc-QPCR, 54% of glucose-excited, 42% of
glucose-inhibited, and 9% of nonglucosensing MAN neu-
rons expressed glucokinase (Table 2). However, UCN3
was isolated from only 2, 16, and 4% of the glucose-excited,
glucose-inhibited, and nonglucosensing neurons, respec-
tively.
Glucokinase, CRH-R2, and UCN3 show different spa-
tial relationships within the MAN. Having shown that
only a minority of glucose-sensing neurons contained
mRNA for UCN3, quantitative real-time PCR was used to
examine the spatial distribution of glucokinase, UCN3, and
CRH-R2 mRNA expression in MAN micropunches. A ros-
trocaudal gradient in glucokinase, UCN3, and CRH-R2
gene expression in the MAN was seen. Both glucokinase
and CRH-R2 expression showed a similar rostrocaudal
distribution, whereas UCN3 showed the opposite rostro-
caudal distribution in the MAN (supplementary Fig. 2,
available in an online appendix).
Lesioning the MAN results in a suppressed counter-
regulatory hormonal response to acute hypoglyce-
mia. To examine whether the MAN contributed to the
generation of a counterregulatory response during acute
hypoglycemia in vivo, the MAN of male Sprague–Dawley
rats was lesioned by direct microinjection of ibotenic acid.
During the subsequent hyperinsulinemic hypoglycemia
study, plasma glucose levels did not differ between MAN
lesioned and control rats (70  1 vs. 69  1 mg/dl,
respectively; Fig. 2A). Glucose infusion rates (GIR) re-
quired to maintain the hypoglycemic plateau were 18%
higher in MAN-lesioned rats (mean GIR over 60–90 min,
24.7  1.7 vs. 20.3  1.4 mg/kg/min), although the overall
interaction was not signiﬁcant (F  4.0; P  0.07; Fig. 2B).
However, MAN lesioning did result in signiﬁcantly im-
paired plasma epinephrine (F  6.0, P  0.05) and
glucagon (F  6.9, P  0.05) responses to the hypoglyce-
mic challenge (Fig. 2C and D).
Localized glucoprivation in the MAN and VMH in the
fasting state has no effect on glucose counterregula-
tion. To determine whether the MAN might respond
directly to a local glucoprivic challenge, the MAN was
locally perfused with 2-DG over 30 min. MAN glucopriva-
tion did not result in a signiﬁcant rise in plasma glucose or
change in plasma levels of glucagon and epinephrine
(Table 3). Application of 2-DG at an identical concentra-
tion and rate to the VMH also failed to elicit a glucoprivic
response (Table 3). Additional studies injecting 5-Thioglu-
cose (a more potent glucoprivic agent) into the MAN or
VMH also had no signiﬁcant effect on glucose or counter-
regulatory hormones (data not shown).
MAN glucoprivation during mild systemic hypoglyce-
mia ampliﬁes the counterregulatory response. In con-
trast to the lack of effect of local MAN glucoprivation
during euglycemia, comparable MAN glucoprivation dur-
ing mild systemic hypoglycemia did alter the subsequent
counterregulatory response. Despite equivalent hypogly-
cemia [mean (SEM) 60–90 min glucose levels, 70  2
TABLE 1
Glucose-responsive MAN neurons
Neuron Number Percentage
GE 32/522 6%
GI 39/522 7.5%
NG 449/522 86.5%
Fura-2 calcium imaging was used to measure changes in Ca
2	I
oscillations while varying glucose concentrations 2.5 to 0.5 to 2.5
mmol/l glucose in neurons isolated from the MAN. GE, glucose-
excited neuron; GI, glucose-inhibited neuron; NG, glucose-
unresponsive neuron.
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FIG. 1. Representative changes in [Ca
2]i oscillations after exposure to incremental dose glucose in freshly dissociated medial amygdalar neurons
from 3–4-week-old male Sprague–Dawley rats. All recordings were carried out in 2.5 mmol/l glucose (2.5 mmol/l glc) followed by two doses of
glucose (0.5 and 2.5 mmol/l), and then tested with glutamate. A: Glucose-excited neuron (n  25) showing increased [Ca
2]i oscillations at 2.5
mmol/l, decreased [Ca
2]i oscillations at 5 mmol/l, and a robust response to glutamate. B: Glucose-inhibited neuron (n  27) showing low [Ca
2]i
oscillations at 0.5 mmol/l and substantial response at 2.5 mmol/l. C: Neuron unresponsive to different physiological levels of glucose (n  14).
TABLE 2
Glucokinase and UCN3 mRNA expression in glucose-excited,
glucose-inhibited, and glucose-unresponsive neurons in the
MAN identiﬁed by Fura-2 calcium imaging, revealed by single-cell
RT-PCR
Neuron Number
Co-expressing
with GK
Co-expressing
with UCN3
GE 46 54% 2%
GI 45 42% 16%
NG 23 9% 4%
GE, glucose-excited neuron; GI, glucose-inhibited neuron; GK, glu-
cokinase; NG, glucose-unresponsive neuron.
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3A], GIR (60–90 min) were threefold lower in the MAN
2-DG infused rats compared with the aECF control group
(3.8  1.1 versus12.3  2.2 mg/kg/min, respectively; F 
24.6, P  0.01) (Fig. 3B). Consistent with the lower GIR,
2-DG microinjection to the MAN signiﬁcantly ampliﬁed the
glucagon (F  4.8, P  0.05) and epinephrine (F  7.2, P 
0.05) responses during hypoglycemia (Figs. 3C and D).
UCN3 neurons innervating the VMH arise primarily
from the MAN. To determine the origin of UCN3 neurons
innervating the VMH, the retrograde neuronal tracer,
WGA, was microinjected into the VMH. While UCN3
neurons are present in the medial preoptic nucleus and the
rostral perifornical area as expected, by double-label im-
munohistochemistry, that most of the UCN3 neurons in
the MAN project to the VMH (cell bodies positive for
[WGA	UCN3]/UCN3  492/520). Moreover, microinjec-
tion of a retrograde tracer to the MAN demonstrated direct
neural pathways in the reciprocal direction from cell
bodies in the VMH to nerve terminals in the MAN (supple-
mentary Fig. 4). A schematic representation of the location
of UCN3 cell bodies innervating the VMH is shown in Fig.
4, whereas microphotographs of cells showing dual label-
ing of UCN3 and WGA in the MAN are shown in supple-
mentary Fig. 3.
Hypoglycemia activates VMH-projecting MAN UCN-3
neurons. To determine whether the UCN3 cell bodies in
the MAN were activated during acute hypoglycemia, rats
underwent hyperinsulinemic hypoglycemic (70 mg/dl) or
hyperinsulinemic euglycemic (120 mg/dl) clamp studies
for 120 min as described above. Using triple ﬂuorescence
immunostaining for cFOS, UCN3, and the retrograde
tracer ﬂuorogold, we found that 30% (155/520 neurons)
of those UCN3 neurons in the MAN that innervate the VMH
coexpressed cFOS, a marker of neuronal activation, dur-
ing acute hyperinsulinemic hypoglycemia when compared
with hyperinsulinemic euglycemia (1/655; P  0.05). This
suggests that at least one-third of the MAN UCN3 neurons
are activated during a mild hypoglycemic stimulus (Fig. 5).
DISCUSSION
The principal ﬁnding of the current study is the novel
discovery that the MAN contains glucose-sensing neurons
that can inﬂuence the magnitude of the counterregulatory
response to insulin-induced hypoglycemia. The amygdala
is a complex structure, containing a number of discrete
nuclei involved in a wide range of behavioral and physio-
logical functions. In the rodent, the MAN is strongly
connected with the olfactory system, has numerous inter-
connections with other amygdalar nuclei (enabling it to
integrate the neural outputs from these different regions),
and, like the VMH, has also been shown to integrate with
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FIG. 2. Lesioning of the MAN leads to suppression of counterregulatory responses to acute hypoglycemia. A: Declines in plasma glucose level in
response to the hyperinsulinemic clamp (70 mg/dl) did not differ between control (white circle) and MAN lesion (black circle) groups. B:
Decreased need for exogenous glucose (decreased glucose infusion rate [GIR]) after MAN lesion. C: Suppressed epinephrine and (D) glucagon
secretory responses to hypoglycemia after MAN lesion. Data are expressed as mean  SE.
TABLE 3
Microinfusion of the nonmetabolizable glucose analog 2-DG to
the VMH and MAN of rats following an overnight fast had no
effect on plasma glucose or counterregulatory hormones
MAN 	 2-DG
(n  6)
VMH 	 2-DG
(n  4)
0 min 60 min 0 min 60 min
Glucose (mg/dl) 114  6 114  7 124  3 112  4
Glucagon (ng/l) 51  38 1  16 72  95 8  9
Epinephrine (pg/ml) 235  66 249  99 208  56 70  45
L. ZHOU AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2649the neural circuits linked to feeding and body weight
control (25,26). Interestingly, a recent study using [
18F]-
ﬂuorodeoxyglucose positron emission tomography, in 13
men with type 1 diabetes, reported reduced [
18F]-ﬂuoro-
deoxyglucose uptake in the amygdala during hypoglyce-
mia in those subjects with hypoglycemia unawareness
failure, suggesting a potential role for the amygdala in the
development of hypoglycemia unawareness (27).
The VMH is integral to glucose-sensing during acute
hypoglycemia (for a review, see ref [28]). The VMH con-
tains specialized glucose-sensing neurons (23), and 14–
19% of these are glucose-excited, whereas 3–14% are
glucose-inhibited in type (29). As in the pancreatic -cell,
glucokinase appears to be a critical regulator of glucose-
sensing in VMH neurons (6), where glucokinase is ex-
pressed in 65% of glucose-excited and 45% of glucose-
inhibited neurons (23). In fact, it is most likely that all
neurons that express glucokinase are actually glucose-
sensing and that the ﬁnding of glucokinase mRNA in
non-glucose-sensing neurons is due to the stringent crite-
ria used to classify neurons. In the present study, we have
been able to show, using fura-2-calcium imaging, that the
expression of glucokinase mRNA in the MAN is associated
with the presence of specialized glucose-sensing neurons.
Of these, 6% were glucose-excited whereas 7.5% were
glucose-inhibited. Moreover, 54% of glucose-excited and
42% of glucose-inhibited, compared with only 9% of non-
glucose-sensing neurons, contained mRNA for glucoki-
nase. These ﬁndings clearly parallel those of the VMH,
providing support for the hypothesis that the MAN may
represent a novel glucose-sensing brain region.
To determine whether the MAN plays a functional role
in glucose-sensing, we initially used the selective neuro-
toxin, ibotenic acid, to lesion the MAN and then performed
a hyperinsulinemic hypoglycemic study. Consistent with a
previous study where ibotenic acid was used to lesion the
VMH (8), lesioning the MAN was shown to suppress the
counterregulatory hormonal response to subsequent hypo-
glycemia. Subsequently, we sought to determine whether
localized glucoprivation in the MAN of euglycemic animals
would induce a glucoprivic response, characterized by a
rise in plasma glucose and in the counterregulatory hor-
mones glucagon and epinephrine, as previously demon-
strated in the VMH (9). However, neither 2-DG nor
5-thioglucose infusions into either the MAN or VMH over
30 min raised plasma glucose, glucagon, or epinephrine
levels. We then sought to determine whether combining
local MAN glucoprivation during a moderate systemic
hypoglycemic stimulus might inﬂuence counterregulatory
responses to assess whether this additional glucoprivic
stimulus might amplify the counterregulatory response. In
fact, the combination of local MAN and systemic glucopri-
vation did have this effect. Taken together, these in vivo
studies suggest that the MAN contributes to the counter-
regulatory response induced by systemic hypoglycemia
but that local glucoprivation in the MAN alone is insufﬁ-
cient to generate a counterregulatory hormone response.
A previous study that used unilateral microinjection to
localize glucose-sensing brain regions also failed to elicit a
glucoprivic response in the majority of hypothalamic
regions tested, although it did produce glucoprivic re-
sponses with unilateral hindbrain microinjections (30).
More recently, bilateral VMH 5-TG microinjections were
shown to stimulate food intake; however, no glucose
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FIG. 3. Provision of an additional glucoprivic stimulus to the MAN ampliﬁes the counterregulatory response to a mild systemic insulin-induced
hypoglycemic challenge. A: Declines in plasma glucose level in response to the hyperinsulinemic clamp (70 mg/dl) did not differ between control
(white circle) and 2-DG (black circle) groups. B: Decreased need for exogenous glucose (decreased glucose infusion rate [GIR]) after 2-DG
injection into the MAN. C: Ampliﬁed epinephrine and (D) glucagon secretory responses to hypoglycemia in MAN 2-DG injected rats. Data are
expressed as mean  SE.
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not measured in our study, but we did not ﬁnd an increase
in blood glucose after VMH 5-TG or 2-DG. The reasons for
these discrepancies are not clear. Borg et al. (9) used
microdialysis to deliver 2-DG locally to the VMH, and it is
possible that, under these conditions, the stimulus to
glucose-sensing neurons is greater. Interestingly, recurrent
glucoprivation impairs hypothalamic but not hindbrain
responses to subsequent hypoglycemia (32), suggesting
that repeated hypoglycemia restrains hindbrain glucose-
sensing via an upstream (hypothalamic and or other brain
region) mechanism. On the basis of the present ﬁndings
and those of Ritter et al. (30), we would speculate that
glucose-sensors in the hindbrain may form part of a
classical sensory reﬂex response, whereas glucose-sen-
sors in higher centers are more integrated in their re-
sponse to a glucoprivation, that is, hypoglycemia might
need to be present in a number of glucose-sensing brain
and/or peripheral sensors before counterregulation is
initiated.
Given the importance of the VMH to the detection of
hypoglycemia and our previous studies showing a role for
UCN3 in the VMH in modulating the counterregulatory
response to hypoglycemia, we then sought to examine
whether UCN3 might link these two glucose-sensing re-
gions. Previous neuroanatomical studies have shown that
the MAN projects topographically to the VMH (25), ﬁnd-
ings conﬁrmed in our study using retrograde neural tracers
to show reciprocal pathways between these two regions.
Additionally, we have been able to demonstrate that most
of the UCN3 projections to the VMH arise in the MAN.
Moreover, using triple-staining immunohistochemistry, we
also found that 1/3 of these activated during acute
hypoglycemia. In this context, our previous ﬁnding that
pharmacological manipulation of CRH-R2 receptors in the
VMH markedly altered counterregulatory responses to
acute hypoglycemia is very suggestive of a functional role
for this neural network (13). It is perhaps counterintuitive
that UCN3 activation in the MAN during hypoglycemia
might lead to suppression of glucose-sensing neurons in
the VMH. However, it is notable that few of the individual
MAN glucose-sensing neurons identiﬁed by Ca
2	 imaging
also expressed mRNA for UCN3. On the other hand, many
did express mRNA for its receptor, CRH-R2. In addition,
gene expression analysis from serial MAN micropunches
showed that glucokinase and CRH-R2 gene expression had
the same rostrocaudal distribution, but the opposite ros-
trocaudal distribution as UCN3 mRNA. This implies that
UCN3 neurons may represent a discrete neuronal popula-
tion in the MAN that are not in themselves glucose-sensing
and, thus, may also directly regulate glucose-sensing neu-
rons locally, as they do in the VMH. This would lead us to
speculate that UCN3 neurons may regulate or coordinate
the output, in terms of the counterregulatory responses,
from these two discrete glucose-sensing regions.
In summary, in the current study we have identiﬁed the
MAN as a novel limbic glucose-sensing region that con-
tains characteristic glucokinase-expressing glucose-sens-
ing neurons that respond directly to manipulations of
glucose availability. In addition, manipulation of the MAN
by lesion or through provision of an additional glucoprivic
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FIG. 4. A schematic diagram illustrating the distribution of UCN3
neurons from serial sections through the MAN. Each open circle
represents a neuronal cell body staining for UCN3 alone, while the
stars show dual staining for UCN3 and WGA. BLA, basolateral amyg-
dalar nucleus; CPu, caudate putamen (Striatum); f, fornix; ic, internal
capsule; mt, mammillothalamic tract; opt, optic tract; Pir, Piriform
cortex; PH, posterior hypothalamic nucleus.
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FIG. 5. High magniﬁcation image of neuronal cell bodies within MAN.
Triple-staining immunohistochemistry was used to indentify UCN3
neurons in the MAN that were activated by hypoglycemia and that
directly innervated the VMH. A: The retrograde tracer ﬂuorogold (FG)
microinjected to the VM and identiﬁed as yellow staining within MAN
neuronal cell bodies (white arrows). B: cFOS immunoreactivity
present within MAN neuronal cell bodies during acute hypoglycemia
(white arrows). C: UCN3 neurons in the MAN (white arrows). D:
Neuronal cell bodies showing FG (blue), cFOS (green), and UCN3
(red). Triple staining is seen in those neurons identiﬁed by white
arrows. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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moderate systemic hypoglycemia. Finally, we have shown
that both these glucose-sensing regions are linked by
UCN3 neurons, which potentially provides a mechanism
for ﬁne-tuning and integrating the stress response during a
hypoglycemic challenge.
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